Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

SRR33346960

3890fb5a-8858-5a3a-818b-a59de3b2facf

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
sex
Male

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.630
  • G2M_CHECKPOINT+0.600
  • MYC_TARGETS_V1+0.580
  • MYC_TARGETS_V2+0.560
  • UNFOLDED_PROTEIN_RESPONSE+0.420
  • MITOTIC_SPINDLE+0.290
  • SPERMATOGENESIS+0.230
  • DNA_REPAIR+0.160
  • MTORC1_SIGNALING+0.140
  • TGF_BETA_SIGNALING+0.060

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.600
  • INTERFERON_GAMMA_RESPONSE-0.460
  • KRAS_SIGNALING_UP-0.370
  • TNFA_SIGNALING_VIA_NFKB-0.370
  • INFLAMMATORY_RESPONSE-0.340
  • IL6_JAK_STAT3_SIGNALING-0.310
  • COAGULATION-0.290
  • FATTY_ACID_METABOLISM-0.280
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.270
  • COMPLEMENT-0.260

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR10900561
melanoma-umap@29
0.911
2SAMN03290940
melanoma-umap@29
0.908
3BS_N6N147BY
brain-umap@2
Embryonal tumors0.904
4AUR-AG0N-TTM1-A-1-1-R-A743-41
breast-umap@18
E0.904
5BS_HE57E1RP
brain-umap@2
medulloblastoma0.903
6TCGA-A1-A0SO-01A-22R-A084-07
breast-umap@18
E0.903
7MNG704
mng-umap@100
0.903
8SRR12696755
melanoma-umap@29
0.902
9BS_M4923M40
brain-umap@2
ATRT0.901
10TCGA-AC-A2BK-01A-11R-A21T-07
breast-umap@18
E0.899

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 10 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.630Inavolisib— uncovered
G2M_CHECKPOINT0.600Inavolisib— uncovered
MYC_TARGETS_V10.580Inavolisib— uncovered
MYC_TARGETS_V20.560Idelalisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.420Idelalisib— uncovered
MITOTIC_SPINDLE0.290Inavolisib— uncovered
SPERMATOGENESIS0.230Inavolisib— uncovered
DNA_REPAIR0.160Idelalisib— uncovered
MTORC1_SIGNALING0.140Inavolisib— uncovered
TGF_BETA_SIGNALING0.060Inavolisib— uncovered